Elan Corporation, plc (ELN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (3166)	9/10/2002 12:40:37 PM
From: Icebrg	Read Replies (1) of 10345

FDA approves Teva's cefaclor ER tablets 06 Sep 2002 The FDA has approved Teva Pharmaceutical's ANDA for cefaclor extended release tablets USP, 375mg and 500mg. This is the first generic approval for the 375mg strength. Shipment of this product is expected to begin immediately. Cefaclor extended release tablets are the AB-rated generic equivalent of Eli Lilly's Ceclor CD, marketed by Elan Corporation. Cefaclor extended release tablets are a cephalosporin antibiotic with annual sales of $14 million. datamonitor.com As far as I see this was not a major set-back for Elan. The drug was already generic and Elan took a write-down of their IP in their 2001 accounts with an amount of mUSD 94,2. Sales during 2001 were 13,4 mUSD. Ice (posted for reference purposes mainly).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next